Abstract
ABSTRACT PTEN and PIK3CA status are potential predictors of response to PI3K-pathway inhibitors. Therefore, we searched the most reliable platform to assess both PTEN expression and PIK3CA mutations in primary and metastatic breast cancer (BC). We cross-validated the assays between different institutions. Studies were performed using four different sample sets of formalin-fixed paraffin-embedded (FFPE) breast cancers from VHUH/VHIO and from Columbia University. PTEN alterations were genotyped in 14 TNBCs by OncoscanTM platform (Affymetrix) and were correlated to immunohistochemistry (IHC). PTEN loss of heterozygosity (LOH, n = 4) with or without overlapping PTEN mutation (n = 5) was concordant to PTEN protein loss (H-Score Disclosure Y. Wang: Yuker Wang is employee of Affymetrix Inc. All other authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
